A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem chłoniaka z dużych komórek B (pierwotny lub powstały z chłoniaka folikularnego)
- •Choroba nawrotowa (powróciła po wcześniejszej remisji trwającej co najmniej 6 miesięcy) lub opora (nie reagowała na leczenie lub pogorszyła się w ciągu 6 miesięcy)
- •Przynajmniej jedno wcześniejsze leczenie systemowe
- •Widoczne guzy w badaniach CT (węzły chłonne ponad 1,5 cm lub guzy poza węzłami ponad 1 cm)
- •Ogólny stan zdrowia pozwalający na ambulatoryjne leczenie
- •Prawidłowe wyniki badań krwi i nerek
✗ Disqualifies
- •Uczestnictwo w wcześniejszych badaniach tego samego leku
- •Pierwsza linia leczenia i kandydat do przeszczepu komórek macierzystych
- •Historia alergii na antybiotyki monoklonalne
- •Wcześniejsze leczenie glofitamabem, gemcytabiną lub oksaliplatyną
- •Schorzenia nerwowe obwodowe
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (53)
Alaska Oncology & Hematology, LLC
Anchorage, United States
Community Cancer Institute (CCI)
Clovis, United States
Providence Medical Foundation
Fullerton, United States
Los Angeles Cancer Network
Glendale, United States
Valkyrie Clinical Trials
Los Angeles, United States
Valkyrie Clinical Trials
Panorama City, United States
Zuckerberg San Francisco General Hospital
San Francisco, United States
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
Torrance, United States
Rocky Mountain Cancer Centers, LLP
Aurora, United States
North Florida/ South Georgia VA Medical Center
Gainesville, United States
Mount Sinai Comprehensive Cancer Center
Miami, United States
Orlando Health Cancer Institute
Orlando, United States
St Luke?s Cancer Institute
Boise, United States
Cancer Care Specialists of Central Illinois
Swansea, United States
Mission Blood and Cancer - MercyOne Cancer Center
Waukee, United States
University of Kentucky - Markey Cancer Center
Lexington, United States
Mary Bird Perkins Cancer Ctr
Baton Rouge, United States
Boston Medical Center
Boston, United States
Corewell Health
Grand Rapids, United States
Nebraska Cancer Specialists
Omaha, United States
New York Oncology Hematology, P.C.
Albany, United States
Hematology Oncology Associates of Central New York
East Syracuse, United States
Oncology Associates of Oregon, P.C
Eugene, United States
Providence Portland Medical Center
Portland, United States
Providence St. Vincent Medical Center
Portland, United States
Tennessee Oncology
Chattanooga, United States
Tennessee Oncology
Nashville, United States
Baylor Scott & White Health
Temple, United States
Texas Oncology - Gulf Coast
The Woodlands, United States
Texas Oncology- Northeast Texas
Tyler, United States
Virginia Cancer Specialists, PC
Fairfax, United States
Virginia Oncology Associates - Virginia Beach
Virginia Beach, United States
Northwest Medical Specialties
Tacoma, United States
Epworth Hospital
East Melbourne, Australia
Arthur J.E. Child Comprehensive Cancer Center
Calgary, Canada
CancerCare Manitoba (CCMB)
Winnipeg, Canada
CHU de Grenoble
La Tronche, France
Chu de Montpellier-St Eloi
Montpellier, France
CHU de Bordeaux
Pessac, France
CHU DE RENNES - CHU Pontchaillou
Rennes, France
Chu De Tours
Tours, France
CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.Hämatologie u.Onkologie
Berlin, Germany
Charite-Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)
Berlin, Germany
Universitätsklinikum Köln
Cologne, Germany
Otto von Guericke Uni Magdeburg Uniklinik
Magdeburg, Germany
Istituto Nazionale Tumori Irccs Fondazione g. Pascale
Naples, Italy
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"
Meldola, Italy
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
Brescia, Italy
Irccs Istituto Europeo Di Oncologia (IEO)
Milan, Italy
Istituto Clinico Humanitas
Rozzano, Italy
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Trial contact
Reference Study ID Number: GO45434 https://forpatients.roche.com/ No email attachments.
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.